Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence

Science Translational Medicine

Volumn 8, Issue 334, 2016, Pages

  Balko, Justin M ^a,b,c   Schwarz, Luis J ^a   Luo, Na ^a   Estrada, Mónica V ^a,c   Giltnane, Jennifer M ^i,j   Dávila González, Daniel ^d   Wang, Kai ^e   Sánchez, Violeta ^a   Dean, Phillip T ^a   Combs, Susan E ^f   Hicks, Donna ^b   Pinto, Joseph A ^g   Landis, Melissa D ^d   Doimi, Franco D ^h   Yelensky, Roman ^e   Miller, Vincent A ^e   Stephens, Phillip J ^e   Rimm, David L ^f   Gómez, Henry ^h   Chang, Jenny C ^d   Sanders, Melinda E ^a,c   Cook, Rebecca S ^b,c   Arteaga, Carlos L ^a,b,c   more..

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e FOUNDATION MEDICINE   (United States)

^f YALE UNIVERSITY   (United States)

^g National Cancer Institute INEN and Oncosalud   (Peru)

^h INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

ⁱ GENENTECH INC   (United States)

^j Gritstone Oncology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BSK 805; DOCETAXEL; DOXYCYCLINE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; N,N DICYCLOPROPYL 4 [(1,5 DIMETHYL 1H PYRAZOL 3 YL)AMINO] 6 ETHYL 1,6 DIHYDRO 1 METHYLIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE 7 CARBOXAMIDE; PACLITAXEL; RUXOLITINIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; STAT6 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; BREAST SURGERY; CANCER INHIBITION; CANCER STAGING; CANCER STEM CELL; CARCINOGENICITY; CELL POPULATION; CHROMOSOME 9P; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; GENE AMPLIFICATION; GENE LOCUS; HUMAN; HUMAN CELL; IN VIVO STUDY; JAK2 GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MIDDLE AGED; MOUSE; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; CELL PROLIFERATION; CHROMOSOME 9; COHORT ANALYSIS; DRUG EFFECTS; ENZYMOLOGY; GENE SILENCING; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 9; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENE KNOCKDOWN TECHNIQUES; GENETIC LOCI; HUMANS; JANUS KINASE 2; MIDDLE AGED; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84963819722     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad3001     Document Type: Article

References (48)

1. J. M. Balko, R. S. Cook, D. B. Vaught, M. G. Kuba, T. W. Miller, N. E. Bhola, M. E. Sanders, N. M. Granja-Ingram, J. J. Smith, I. M. Meszoely, J. Salter, M. Dowsett, K. Stemke-Hale, A. M. González-Angulo, G. B. Mills, J. A. Pinto, H. L. Gómez, C. L. Arteaga, Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18, 1052-1059 (2012).
2. J. M. Balko, J. M. Giltnane, K. Wang, L. J. Schwarz, C. D. Young, R. S. Cook, P. Owens, M. E. Sanders, M. G. Kuba, V. Sánchez, R. Kurupi, P. D. Moore, J. A. Pinto, F. D. Doimi, H. Gómez, D. Horiuchi, A. Goga, B. D. Lehmann, J. A. Bauer, J. A. Pietenpol, J. S. Ross, G. A. Palmer, R. Yelensky, M. Cronin, V. A. Miller, P. J. Stephens, C. L. Arteaga, Molecular profiling of the residual disease of triplenegative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 4, 232-245 (2014).
3. J. A. Bauer, A. B. Chakravarthy, J. M. Rosenbluth, D. Mi, E. H. Seeley, N. De Matos Granja-Ingram, M. G. Olivares, M. C. Kelley, I. A. Mayer, I. M. Meszoely, J. A. Means-Powell, K. N. Johnson, C. J. Tsai, G. D. Ayers, M. E. Sanders, R. J. Schneider, S. C. Formenti, R. M. Caprioli, J. A. Pietenpol, Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res. 16, 681-690 (2010).
4. L. L. Marotta, V. Almendro, A. Marusyk, M. Shipitsin, J. Schemme, S. R. Walker, N. Bloushtain-Qimron, J. J. Kim, S. A. Choudhury, R. Maruyama, Z. Wu, M. Gönen, L. A. Mulvey, M. O. Bessarabova, S. J. Huh, S. J. Silver, S. Y. Kim, S. Y. Park, H. E. Lee, K. S. Anderson, A. L. Richardson, T. Nikolskaya, Y. Nikolsky, X. S. Liu, D. E. Root, W. C. Hahn, D. A. Frank, K. Polyak, The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-2735 (2011).
5. W. T. Khaled, E. K. C. Read, S. E. Nicholson, F. O. Baxter, A. J. Brennan, P. J. Came, N. Sprigg, A. N. J. McKenzie, C. J. Watson, The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. Development 134, 2739-2750 (2007).
6. K. Shuai, B. Liu, Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900-911 (2003).
7. A. Sonnenblick, B. Uziely, H. Nechushtan, L. Kadouri, E. Galun, J. H. Axelrod, D. Katz, H. Daum, T. Hamburger, B. Maly, T. M. Allweis, T. Peretz, Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 138, 407-413 (2013).
8. H. Yu, H. Lee, A. Herrmann, R. Buettner, R. Jove, Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer 14, 736-746 (2014).
9. B. J. Shields, F. Wiede, E. N. Gurzov, K. Wee, C. Hauser, H.-J. Zhu, T. J. Molloy, S. A. O'Toole, R. J. Daly, R. L. Sutherland, C. A. Mitchell, C. A. McLeang, T. Tiganisa, TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol. Cell. Biol. 33, 557-570 (2013).
10. J. Wu, S. Liu, G. Liu, A. Dombkowski, J. Abrams, R. Martin-Trevino, M. S. Wicha, S. P. Ethier, Z.-Q. Yang, Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene 31, 333-341 (2012).
11. S. S. Yip, A. J. Crew, J.M. Gee, R. Hui, R. W. Blamey, J. F.R. Robertson, R. I.Nicholson, R. L. Sutherland, R. J. Daly, Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int. J. Cancer 88, 363-368 (2000).
12. T Bachelot, I. Ray-Coquard, C. Menetrier-Caux, M. Rastkha, A. Duc, J.-Y. Blay, Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br. J. Cancer 88, 1721-1726 (2003).
13. K. S. Selander, L. Li, L. Watson, M. Merrell, H. Dahmen, P. C. Heinrich, G. Müller-Newen, K. W. Harris, Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res. 64, 6924-6933 (2004).
14. J. C. Lieblein, S. Ball, B. Hutzen, A. K. Sasser, H.-J. Lin, T. H. M. Huang, B. M. Hall, J. Lin, STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 8, 302 (2008).
15. R. Garcia, T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. Muro-Cacho, C. E. Cox, R. Falcone, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A. Levitzki, A. Kraker, R. Jove, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513 (2001).
16. K. Yokogami, S. Wakisaka, J. Avruch, S. A. Reeves, Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 10, 47-50 (2000).
17. K. D. Sutherland, G. J. Lindeman, D.Y. Choong, S. Wittlin, L. Brentzell, W. Phillips, I. G. Campbell, J. E. Visvader, Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23, 7726-7733 (2004).
18. Z. Q. Yang, K. L. Streicher, M. E. Ray, J. Abrams, S. P. Ethier, Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res. 66, 11632-11643 (2006).
19. Z.-Q. Yang, G. Liu, A. Bollig-Fischer, C. N. Giroux, S. P. Ethier, Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 70, 8487-8497 (2010).
20. C. S. Sinclair, M. Rowley, A. Naderi, F. J. Couch, The 17q23 amplicon and breast cancer. Breast Cancer Res. Treat. 78, 313-322 (2003).
21. K. N. Ogston, I. D. Miller, S. Payne, A. W. Hutcheon, T. K. Sarkar, I. Smith, A. Schofield, S. D. Heys, A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 12, 320-327 (2003).
22. G. Liu, A. Bollig-Fischer, B. Kreike, M. J. van de Vijver, J. Abrams, S. P. Ethier, Z.-Q. Yang, Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28, 4491-4500 (2009).
23. P. Sansone, G. Storci, S. Tavolari, T. Guarnieri, C. Giovannini, M. Taffurelli, C. Ceccarelli, D. Santini, P. Paterini, K. B. Marcu, M. Bonafè, IL-6 triggers malignant features in mammospheres from human ductalbreast carcinomaand normalmammary gland. J. Clin. Invest. 117, 3988-4002 (2007).
24. Z. C. Hartman, G. M. Poage, P. den Hollander, A. Tsimelzon, J. Hill, N. Panupinthu, Y. Zhang, A. Mazumdar, S. G. Hilsenbeck, G. B. Mills, P. H. Brown, Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73, 3470-3480 (2013).
25. Z.-Q. Lin, T. Kondo, Y. Ishida, T. Takayasu, N. Mukaida, Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J. Leukoc. Biol. 73, 713-721 (2003).
26. X. Zhang, S. Claerhout, A. Prat, L. E. Dobrolecki, I. Petrovic, Q. Lai, M. D. Landis, L. Wiechmann, R. Schiff, M. Giuliano, H. Wong, S. W. Fuqua, A. Contreras, C. Gutierrez, J. Huang, S. Mao, A. C. Pavlick, A. M. Froehlich, M.-F. Wu, A. Tsimelzon, S. G. Hilsenbeck, E. S. Chen, P. Zuloaga, C. A. Shaw, M. F. Rimawi, C. M. Perou, G. B. Mills, J. C. Chang, M. T. Lewis, A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73, 4885-4897 (2013).
27. A. Quintas-Cardama, K. Vaddi, P. Liu, T. Manshouri, J. Li, Peggy A. Scherle, E. Caulder, X. Wen, Y. Li, P. Waeltz, M. Rupar, T. Burn, Y. Lo, J. Kelley, M. Covington, S. Shepard, J. D. Rodgers, P. Haley, H. Kantarjian, J. S. Fridman, S. Verstovsek, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109-3117 (2010).
28. F. Baffert, C. H. Régnier, A. De Pover, C. Pissot-Soldermann, G. A. Tavares, F. Blasco, J. Brueggen, P. Chène, P. Drueckes, D. Erdmann, P. Furet, M. Gerspacher, M. Lang, D. Ledieu, L. Nolan, S. Ruetz, J. Trappe, E. Vangrevelinghe, M. Wartmann, L. Wyder, F. Hofmann, T. Radimerski, Potent and selective inhibition of Polycythemia by the quinoxaline JAK2 inhibitor NVPBSK805. Mol. Cancer Ther. 9, 1945-1955 (2010).
29. A. M. Calcagno, C. D. Salcido, J.-P. Gillet, C.-P. Wu, J. M. Fostel, M. D. Mumau, M. M. Gottesman, L. Varticovski, S. V. Ambudkar, Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 102, 1637-1652 (2010).
30. N. E. Bhola, J. M. Balko, T. C. Dugger, M. G. Kuba, V. Sánchez, M. Sanders, J. Stanford, R. S. Cook, C. L. Arteaga, TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123, 1348-1358 (2013).
31. M. R. Green, S. Monti, S. J. Rodig, P. Juszczynski, T. Currie, E.O'Donnell, B. Chapuy, K. Takeyama, D. Neuberg, T. R. Golub, J. L. Kutok, M. A. Shipp, Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
32. S. Joos, M. Granzow, H. Holtgreve-Grez, R. Siebert, L. Harder, J. I. Martín-Subero, J. Wolf, M. Adamowicz, T. F.E. Barth, P. Lichter, A. Jauch, Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int. J. Cancer 103, 489-495 (2003).
33. A. Errico Immunotherapy: PD-1-PD-L1 axis: Efficient checkpoint blockade against cancer. Nat. Rev. Clin. Oncol. 12, 63 (2015).
34. L. Rui, N. C. Emre, M. J. Kruhlak, H.-J. Chung, C. Steidl, G. Slack, G. W. Wright, G. Lenz, V. N. Ngo, A. L. Shaffer, W. Xu, H. Zhao, Y. Yang, L. Lamy, R. E. Davis, W. Xiao, J. Powell, D. Maloney, C. J. Thomas, P. Möller, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, K. Savage, J. M. Connors, L. M. Rimsza, E. Campo, E. S. Jaffe, J. Delabie, E. B. Smeland, D. D. Weisenburger, W. C. Chan, R. D. Gascoyne, D. Levens, L. M. Staudt, Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18, 590-605 (2010).
35. S. Verstovsek, R. A. Mesa, J. R. Gotlib, R. Levy, V. Gupta, Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J. Clin. Oncol. 29, 6500 (2011).
36. T. U. Barbie, G. Alexe, A. R. Aref, S. Li, Z. Zhu, X. Zhang, Y. Imamura, T. C. Thai, Y. Huang, M. Bowden, J. Herndon, T. J. Cohoon, T. Fleming, P. Tamayo, J. P. Mesirov, S. Ogino, K.-K. Wong, M. J. Ellis, W. C. Hahn, D. A. Barbie, W. E. Gillanders, Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J. Clin. Invest. 124, 5411-5423 (2014).
37. B. E. Barton, J. G. Karras, T. F. Murphy, A. Barton, H. F.-S. Huang, Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. 3, 11-20 (2004).
38. A. Britschgi, R. Andraos, H. Brinkhaus, I. Klebba, V. Romanet, U.Müller, M. Murakami, T. Radimerski, M. Bentires-Alj, JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for cotargeting these pathways inmetastatic breast cancer. Cancer Cell 22, 796-811 (2012).
39. R. L. Camp, G. G. Chung, D. L. Rimm, Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8, 1323-1328 (2002).
40. A. McCabe, M. Dolled-Filhart, R. L. Camp, D. L. Rimm, Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J. Natl. Cancer Inst. 97, 1808-1815 (2005).
41. J. R. Brown, H. Wimberly, D. R. Lannin, C. Nixon, D. L. Rimm, V. Bossuyt, Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin. Cancer Res. 20, 5995-6005 (2014).
42. J. M. Balko, B. R. Jones, V. L. Coakley, E. P. Black, MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. Cancer Biol. Ther. 8, 522-530 (2009).
43. B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy, Y. Shyr, J. A. Pietenpol, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767 (2011).
44. J. M. Balko, L. J. Schwarz, N. E. Bhola, R. Kurupi, P. Owens, T. W. Miller, H. Gómez, R. S. Cook, C. L. Arteaga, Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 73, 6346-6358 (2013).
45. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289-300 (1995).
46. The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
47. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehár, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jané-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi, M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W.Winckler, M. Reich, N. Li, J. P. Mesirov, S. B. Gabriel, G. Getz, K. Ardlie, V. Chan, V. E. Myer, B. L. Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris, M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
48. E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, A. Jacobsen, C. J. Byrne, M. L. Heuer, E. Larsson, Y. Antipin, B. Reva, A. P. Goldberg, C. Sander, N. Schultz, The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).